AMA Suggests Ways to Encourage Use of Patient Portals
Suggestions include training staff on portal use; showing patients how to use the portal
Wildfires Can Trigger Acute Coronary Events for Miles Around
Strongest association seen for men and people 65 and older
Considerable Burden for Community-Acquired Pneumonia
Incidence of community-acquired pneumonia requiring hospitalization is highest in elderly
Guidelines Updated for Idiopathic Pulmonary Fibrosis Treatment
Panel strongly against use of anticoagulation, imatinib, endothelin receptor antagonist
Arts Observation Curriculum May Be Beneficial for Medical Students
Learning to observe objectively and communicate observations important in clinical practice
Progress in Reporting Conflict of Interest Among IRB Members
Percentage of members who felt another member didn't disclose financial relationships down '05 to '14
Second Severe Allergic Reaction Within Hours Isn’t Uncommon
Researchers find about one in seven children have repeat episode
Strategies Needed to Combat Weight Gain in Smoking Cessation
Considerably greater weight gain seen in North American versus Asian studies
Structured Exercise Prevents Sleep Issues in Older Adults
However, physical activity intervention not found to resolve existing sleep issues
![Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer with a specific genetic mutation (epidermal growth factor receptor [EGFR]). A just-approved companion diagnostic test can identify patients who could benefit from this new use.](https://www.ehealth-news.com/wp-content/uploads/2016/01/fdalogo-6-180x84.jpg "FDA Approves Iressa for EGFR+ Metastatic Lung Cancer")
FDA Approves Iressa for EGFR+ Metastatic Lung Cancer
New companion diagnostic kit can identify candidates
